New england peptide INC: generation and characterization of modified peptides and generation of monoclonal antibodies specifically recognizing these modified peptides
Ended Purchase Order Awarded Last action
- Contract number
- 75N95020P00617
- Awardee
-
Vivitide LLC UEI UFTCY9CFV8J3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $34,160
Award facts
- Opportunity
-
- Generation and characterization of modified peptides and generation of monoclonal antibodies specifically recognizing these modified peptides Pre-Solicitation · HHSNIHNIDACSS2000754 · Posted Jul 15, 2020
- Generation and characterization of modified peptides and generation of monoclonal antibodies specifically recognizing these modified peptides Award Notice · Posted Sep 23, 2020
- Contract value 100% obligated
- $34,160.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 3 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Gardner, MA 01440, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$6,875 | |
| Funding Only Action | -$80 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $41,115 |
About this award
Vivitide LLC (doing business as New England Peptide) was awarded a $34,160 firm fixed price purchase order by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health under the Department of Health and Human Services. The contract, awarded on September 30, 2020, with an ultimate completion date of September 29, 2022, calls for the generation and characterization of modified peptides and the generation of monoclonal antibodies specifically recognizing these modified peptides. The work will be performed in Gardner, Massachusetts. No small business set-aside designation was applied to this competitive procurement.
Vivitide LLC is an established provider of laboratory supplies and custom peptide synthesis services to federal agencies, with particular expertise in supporting drug discovery and preclinical development activities. The company has maintained an ongoing relationship with multiple components of the National Institutes of Health, including the National Institute on Aging, National Institute of Allergy and Infectious Diseases, and National Institute of Child Health and Human Development, as well as the Centers for Disease Control and Prevention. This award reflects NIDA's continuing need for specialized peptide and antibody development services to support its drug abuse research mission.
Quick answers
Who was awarded contract 75N95020P00617?
75N95020P00617 was awarded to Vivitide LLC by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2020.
How much is contract 75N95020P00617 worth?
The government has obligated $34,160 on 75N95020P00617.
Was contract 75N95020P00617 competed?
The extent of competition for 75N95020P00617 was competed under sap. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award